GlowSense is raising AUD $500,000 seed capital to commercialise the One Pot Process (OPP) Method — the world's first patent-pending cold-process marine bio-spicule co-formulation technology, with zero global prior art confirmed across six jurisdictions.
Seed round · Angel investors
6 global jurisdictions confirmed
Revenue-generating from Day 1
Government co-investment in R&D
Tax incentive for qualifying investors
GlowSense is assessing ESIC (Early Stage Innovation Company) eligibility — a Commonwealth tax incentive offering qualifying angel investors a 20% non-refundable tax offset on investment in newly issued ordinary shares, plus a 10-year CGT exemption on gains. A Private Binding Ruling from the ATO is being pursued before share issuance. ESIC status must be confirmed independently — enquire for current status.
OPP Niacinamide and Vitamin C serums live on glowsense.com.au and Amazon AU. First consumer revenue from OPP-branded products.
3+ signed contract manufacturing clients at 2,000–5,000 unit tiers. Target $200K+ ARR from manufacturing revenue alone.
Quantitative HPLC active stability validation completed — enabling stronger clinical claims and investor-grade evidence documentation.
Global patent filed across US, EU, UK, Japan and South Korea — unlocking international licensing programme and multinational partnership conversations.
The OPP cold-process bio-spicule co-formulation method has zero global prior art across AU, US, EP, CN, KR and WO jurisdictions. This is not a formulation trade secret — it is a formally filed patent protecting the process. No competitor can replicate the OPP claim without infringing AU 2026901796.
GlowSense is not pre-revenue. We are ISO 22716 GMP certified and manufacturing for B2B clients today. The seed raise accelerates growth of an already-operational business with a confirmed client pipeline and quoted pricing across multiple SKUs and volume tiers.
The OPP mechanism is grounded in PubMed-indexed research (Zhang et al., 2017 — 33–72× enhancement confirmed in porcine skin and BALB/c mice). This is not hypothetical — it is reproducible, published science that GlowSense has applied as a novel manufacturing method.
Contract manufacturing provides immediate, predictable B2B revenue. The GlowSense consumer brand provides scalable DTC margin. B2B validates the technology; DTC builds brand equity and consumer data. Both revenue streams benefit from the same OPP platform IP.
GlowSense operates a two-entity structure designed to protect IP from operational risk. The operating entity (GlowSense Pty Ltd) runs manufacturing and commercial operations. The IP-holding entity (GlowSense Holdings Pty Ltd) owns the patent and licenses it to the operating entity — a standard IP protection structure appropriate for investor-backed technology companies.
Seed investment is being accepted into the operating entity (GlowSense Pty Ltd) via newly-issued ordinary shares. ESIC eligibility for investor tax benefits is under assessment via Private Binding Ruling pathway. Investors should obtain independent tax advice.
We are happy to share our investor deck, financial model and R&D documentation under NDA. All investment discussions are confidential.